Genicular Nerve Block in Juvenile Idiopathic Arthritis

• Status: Completed
• Trial end date: 2021-02-15
• Target enrollment: 0
• Participant gender: All

Summary

N=104 juvenile idiopathic arthritis patients diagnosed after ILAR criteria with unilateral persistent knee arthritis. They will be randomly assigned into two groups; group 1 will receive genicular nerve block, group 2 intra-articular triamcinolone. Both groups will be examined by SOLAR ultrasound scoring system, Visual analogue scale and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score will be used to assess tenderness and swelling at the same intervals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sohag University

Criteria

Inclusion Criteria:

• juvenile idiopathic arthritis with persistent knee arthritis

• age below 16

Exclusion Criteria:

• severe knee osteoarthritis

• peripheral neuropathy,

• psoriatic arthritis,

• those under anticoagulant therapy, skin infection,

• prior knee injection in the last 3 months3

• those who have an allergy to Bupivacaine